Clinical and basic research advances on Jinlong capsule for the prevention and treatment of liver cancer
Frontiers in Pharmacology · 09.06.2025 · 16
DOI: 10.3389/fphar.2025.1522945 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 09.06.2025. Verfasst von Liyuan Lv und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Primary liver cancer, characterized by an insidious onset, rapid progression, high degree of heterogeneity, difficulties in treatment, and a short survival time, poses a significant threat to human health. Jinlong capsule (JLC), an original drug developed in China, is a Chinese patent medicine used to treat liver cancer. Research has demonstrated the antitumor effects of JLC, attributed to its unique preparation process. When used in combination with modern treatment methods, JLC helps in preventing and treating liver cancer recurrence and metastasis, prolonging patient survival, increasing the tumor objective response rate, alleviating gastrointestinal adverse reactions, enhancing survival quality, regulating immune functions of the body, relieving clinical symptoms, and improving patient safety. This study provides a review of clinical and basic research results on JLC.
Methods
We performed literature searches in the Cochrane Library, Embase, PubMed, OVID Scopus, China Biology Medicine, China National Knowledge Infrastructure, VIP, and Wanfang databases for articles published from database inception to December 2023.
Results
Basic research has revealed that the effects of JLC include the inhibition of tumor growth in vivo and in vitro and immune modulation. The possible mechanisms include inhibiting tumor cell proliferation, promoting tumor cell apoptosis, inhibiting angiogenesis, and modulating cellular immunity.
Discussion
By attuning to the complex biological characteristics of liver cancer, harnessing the unique and unconventional advantages of traditional Chinese medicine, and focusing on clinical needs, we propose directions for future evidence-based research on using JLC in the prevention and treatment of liver cancer. This will contribute to the development of precision synergistic strategies that combine traditional Chinese medicine and modern medicine treatment methods.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
- Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
- Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Zitieren
APA
Lv, L., Ren, S., Zhang, Z., Lin, H., & Liu, J. (2025). Clinical and basic research advances on Jinlong capsule for the prevention and treatment of liver cancer. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1522945
Vancouver
Lv L, Ren S, Zhang Z, Lin H, Liu J. Clinical and basic research advances on Jinlong capsule for the prevention and treatment of liver cancer. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1522945
BibTeX
@article{Lv2025,
author = {Lv, Liyuan and Ren, Simeng and Zhang, Zunyi and Lin, Hongsheng and Liu, Jie},
title = {Clinical and basic research advances on Jinlong capsule for the prevention and treatment of liver cancer},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1522945}
}
EUVIMED